Ortho Evra Adds More Blood Clot Warnings To Label
This article was originally published in The Pink Sheet Daily
Executive Summary
New epidemiology study supports previous findings of increased venous thromboembolism risk with J&J’s birth control patch.
You may also be interested in...
Blood Clot Risks For Yasmin, Yaz, Ortho Evra Get Panel Review After FDA Epidemiology Study
FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees will discuss the benefits and risks of drospirenone-containing drugs and the Ortho Evra patch at a two-day meeting in December.
Blood Clot Risks For Yasmin, Yaz, Ortho Evra Get Panel Review After FDA Epidemiology Study
FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees will discuss the benefits and risks of drospirenone-containing drugs and the Ortho Evra patch at a two-day meeting in December.
Public Citizen Demands Removal of J&J’s Ortho Evra Patch From Marketplace
Petition to FDA claims drug exposes women to 60 percent more estrogen and may increase the risk of blood clots two-fold.